MedTrace Logo

Fatigue and Quality of Life in Patients With Neuroendocrine Neoplasia

NCT04557137 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-09-21

No results posted yet for this study

Summary

Numerous studies describe HRQoL in other cancer types, whereas only sparse research has been done in NEN patients. We wish to investigate HRQol in NEN patients. Using a validated generic tool with normative values derived from a background population, allows us to compare the values healthy controls.

Methods

Study A:

A cross-sectional study that investigates 250 patients (Cohort A) with neuroendocrine neoplasia, encompassing both patients with neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC).

Study B:

A prospective study that investigates 30 newly diagnosed NET patients over three months (Cohort B) who are offered palliative treatment with somatostatin analogues.

Conditions

  • Neuroendocrine Tumors (NET) Health Related Qualito of Life (HRQoL)

Interventions

DRUG

Somatostatin analog

120 mg ipstyl every 28 days

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2022-09-01
Completion
2023-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04557137 on ClinicalTrials.gov